HSD17B13 and metabolic dysfunction-associated steatotic liver disease: Genetic association studies have identified a protective HSD17B13 variant that confers decreased protein stability and reduced enzymatic activity 39, thereby mitigating progression from NAFLD to non-alcoholic steatohepatitis, liver fibrosis 17,39, and hepatocellular carcinoma 17.